TY - JOUR
T1 - Microglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations
AU - Sakae, Nobutaka
AU - Roemer, Shanu F.
AU - Bieniek, Kevin F.
AU - Murray, Melissa E.
AU - Baker, Matthew C.
AU - Kasanuki, Koji
AU - Graff-Radford, Neill R.
AU - Petrucelli, Leonard
AU - Van Blitterswijk, Marka
AU - Rademakers, Rosa
AU - Dickson, Dennis W.
N1 - Funding Information:
Funding Information We are grateful to Linda Rousseau (Mayo Clinic), Ariston L Librero and Virginia Phillips (Mayo Clinic) for histological support, and Monica Castanedes-Casey (Mayo Clinic) for immunohistochemistry support. This study was supported by National Institutes of Health (NIH) grants P01 NS084974, P50 AG016574, R35 NS097261, and R35 NS097273. We thank the patients and their families who donated brains to help further our knowledge of neurodegeneration. We are grateful to Linda Rousseau (Mayo Clinic), Ariston L Librero and Virginia Phillips (Mayo Clinic) for histological support, and Monica Castanedes-Casey (Mayo Clinic) for immunohistochemistry support. This study was supported by National Institutes of Health (NIH) grants P01 NS084974, P50 AG016574, R35 NS097261, and R35 NS097273.
Publisher Copyright:
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - Objective: To identify clinicopathological differences between frontotemporal lobar degeneration (FTLD) due to mutations in progranulin (FTLD-GRN) and chromosome 9 open reading frame 72 (FTLD-C9ORF72). Methods: We performed quantitative neuropathologic comparison of 17 FTLD-C9ORF72 and 15 FTLD-GRN with a focus on microglia. For clinical comparisons, only cases with high quality medical documentation and concurring diagnoses by at least two neurologists were included (14 FTLD-GRN and 13 FTLD-C9ORF72). Neuropathological analyses were limited to TDP-43 Type A to assure consistent assessment between the groups, acknowledging that Type A is a minority of C9ORF72 patients. Furthermore, only cases with sufficient tissue from all regions were studied (11 FTLD-GRN and 11 FTLD-C9ORF72). FTLD cases were also compared to age– and sex–matched normal controls. Immunohistochemistry was performed for pTDP-43, IBA-1, CD68, and GFAP. Morphological characterization of microglia was performed in sections of cortex blinded to clinical and genetic information. Results: FTLD-GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD-C9ORF72 had greater hippocampal tau pathology and more TDP-43 neuronal cytoplasmic inclusions. FTLD-GRN had more neocortical microvacuolation, as well as more IBA-1–positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD-GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD-GRN and FTLD-C9ORF72 differed from controls. Interpretation: Our findings underscore differences in microglial response in FTLD-C9ORF72 and FTLD-GRN as shown by significant differences in ameboid microglia in gray and white matter. These results suggest the differential contribution of microglial dysfunction in FTLD-GRN and FTLD-C9ORF72 and suggest that clinical, neuroimaging and pathologic differences could in part be related to differences in microglia response.
AB - Objective: To identify clinicopathological differences between frontotemporal lobar degeneration (FTLD) due to mutations in progranulin (FTLD-GRN) and chromosome 9 open reading frame 72 (FTLD-C9ORF72). Methods: We performed quantitative neuropathologic comparison of 17 FTLD-C9ORF72 and 15 FTLD-GRN with a focus on microglia. For clinical comparisons, only cases with high quality medical documentation and concurring diagnoses by at least two neurologists were included (14 FTLD-GRN and 13 FTLD-C9ORF72). Neuropathological analyses were limited to TDP-43 Type A to assure consistent assessment between the groups, acknowledging that Type A is a minority of C9ORF72 patients. Furthermore, only cases with sufficient tissue from all regions were studied (11 FTLD-GRN and 11 FTLD-C9ORF72). FTLD cases were also compared to age– and sex–matched normal controls. Immunohistochemistry was performed for pTDP-43, IBA-1, CD68, and GFAP. Morphological characterization of microglia was performed in sections of cortex blinded to clinical and genetic information. Results: FTLD-GRN patients had frequent asymmetric clinical features, including aphasia and apraxia, as well as more asymmetric cortical atrophy. Neuropathologically, FTLD-C9ORF72 had greater hippocampal tau pathology and more TDP-43 neuronal cytoplasmic inclusions. FTLD-GRN had more neocortical microvacuolation, as well as more IBA-1–positive ameboid microglia in superficial cortical layers and in subcortical white matter. FTLD-GRN also had more microglia with nuclear condensation, possibly indicating apoptosis. Microglial morphology with CD68 immunohistochemistry in FTLD-GRN and FTLD-C9ORF72 differed from controls. Interpretation: Our findings underscore differences in microglial response in FTLD-C9ORF72 and FTLD-GRN as shown by significant differences in ameboid microglia in gray and white matter. These results suggest the differential contribution of microglial dysfunction in FTLD-GRN and FTLD-C9ORF72 and suggest that clinical, neuroimaging and pathologic differences could in part be related to differences in microglia response.
UR - http://www.scopus.com/inward/record.url?scp=85070951850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070951850&partnerID=8YFLogxK
U2 - 10.1002/acn3.50875
DO - 10.1002/acn3.50875
M3 - Article
C2 - 31448566
AN - SCOPUS:85070951850
SN - 2328-9503
VL - 6
SP - 1782
EP - 1796
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 9
ER -